A Fusogenic Oncolytic Herpes Simplex Virus for Therapy of Advanced Ovarian Cancer
Abstract
The tasks that were originally planned for the first year of this 3 year project are to demonstrate that the fusogenic oncolytic herpes simplex viruses are potent anti-tumor agents for advanced ovarian cancer. Specifically we planned to: 1) produce a large quantity of high grade and high titer viral stocks for the in vivo animal experiments: 2) establish advanced ovarian cancer in the animal model: 3) to therapeutically administer virus, and to evaluate the therapeutic results. We have now successfully finished these tasks. We initially prepared a large stock of the doubly fusogenic oncolytic HSV Synco-2D. We then characterized Synco-2D in vitro and the result showed that its infection produced a distinctive syncytial phenotype, leading to a significantly increased tumor cell killing ability, compared with that of a nonfusogenic virus (Baco-1). Next we directly injected both Synco-2D and Baco-1 (as control) into the abdominal cavity of mice bearing human ovarian cancer xenografts, Synco-2D eradicated all tumor masses in 75% of the animals, whereas no animals in Baco- 1-treated group was tumor-free. These results demonstrate that the doubly fusogenic Synco-2D is indeed an effective therapeutic agent against advanced ovarian cancer. We are now planning to execute the tasks planned for year 2.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2004
- Accession Number
- ADA426841
Entities
People
- Xiaoliu Zhang
Organizations
- Baylor College of Medicine